美国球囊后凸成形术与椎体成形术对比保守医学管理的成本效益分析
该研究构建1000例患者的马尔可夫微观模拟模型,基于美国Medicare索赔数据,评估球囊后凸成形术(BKP)和椎体成形术(VP)对比保守医学管理(CMM)治疗骨质疏松性椎体压缩骨折的成本效益。结果显示住院BKP、门诊BKP、住院VP和门诊VP的增量成本效果比分别为每获得一个质量调整生命年43455美元、10922美元、39774美元和12293美元,在50000美元/QALY的美国支付意愿阈值下,BKP和VP分别在80%和100%的模拟中被认为具有成本效益。
要点
- 住院BKP对比CMM的ICER为每QALY 43455美元,门诊BKP对比CMM为10922美元。
- 住院VP对比CMM的ICER为每QALY 39774美元,门诊VP对比CMM为12293美元。
- 在50000美元/QALY阈值下,BKP和VP分别在80%和100%的500次模拟中被认为具有成本效益。
核心结论
- 虽然VP和BKP在短期内比CMM更昂贵,但模型结果表明,在适合手术的患者中,以美国支付意愿阈值衡量,介入治疗具有成本效益。
- 该结论支持在欧盟成员国进行的经济分析所得出的结论。
研究设计与样本
- 构建了包含1000例患者的马尔可夫微观模拟模型。
- 成本数据基于对Medicare索赔付款的分析,并对BKP和VP对比对照组(CMM)进行了倾向性评分匹配。
- 死亡率输入基于美国生命表,并根据初始骨折年龄、后续骨折的存在以及按治疗分组的死亡相对风险进行了调整。
- 分别计算了BKP和VP在住院和门诊手术治疗场所的增量成本效果比(ICER),以反映各场所就诊患者的个体临床特征。
主要发现
- 住院BKP对比CMM的贴现ICER为每获得一个QALY 43455美元;门诊BKP对比CMM为10922美元;住院VP对比CMM为39774美元;门诊VP对比CMM为12293美元。
- 概率敏感性分析证实,在50000美元/QALY的美国支付意愿阈值下,BKP和VP分别在80%和100%的500次模型模拟中被认为对比CMM具有成本效益。
- 最敏感的参数的包括生活质量估计值和死亡风险比。
关键数值与推荐
- 住院BKP对比CMM的ICER为每QALY 43455美元。
- 门诊BKP对比CMM的ICER为每QALY 10922美元。
- 住院VP对比CMM的ICER为每QALY 39774美元。
- 门诊VP对比CMM的ICER为每QALY 12293美元。
- 美国支付意愿阈值为50000美元/QALY。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The cost-effectiveness of surgical versus conservative medical management of vertebral compression fractures in the US was analyzed in the context of inpatient versus outpatient treatment. Surgical intervention (balloon kyphoplasty and vertebroplasty) was found to be cost-effective relative to conservative medical management at a US willingness-to-pay threshold. INTRODUCTION: To date, only one published study has evaluated the cost-effectiveness (C/E) of balloon kyphoplasty (BKP) or vertebroplasty (VP) in US Medicare patients with osteoporotic vertebral compression fractures. This study further evaluates the C/E of surgical treatment vs. conservative medical management (CMM), expanding on prior modeling by accounting for quality-adjusted life-years gained. METHODS: A Markov microsimulation model of 1000 patients was constructed. Cost data were based on an analysis of Medicare claims payments, with propensity-score matching performed for BKP and VP vs. controls (CMM). Mortality inputs were based on US life tables, modified to account for age at initial fracture, presence of subsequent fracture(s), and relative risk of mortality by treatment. Separate incremental cost-effectiveness ratios (ICERs) were calculated for BKP and VP in inpatient and outpatient surgical treatment locations to account for individual clinical profiles presenting to each. RESULTS: The discounted ICER for inpatient BKP vs. CMM was $43,455 per QALY gained; for outpatient BKP vs. CMM, $10,922; for inpatient VP vs. CMM, $39,774; and for outpatient VP vs. CMM, $12,293. Probabilistic sensitivity analysis confirmed that both BKP and VP would be considered C/E vs. CMM at a US willingness-to-pay (WTP) threshold of $50,000/QALY in 80% and 100% of 500 model simulations, respectively. The most sensitive parameters included quality of life estimates and hazard ratios for mortality. CONCLUSION: While VP and BKP are more expensive treatment options than CMM in the short term, model results suggest interventional treatment is cost-effective, among patients eligible for surgery, at a US WTP threshold. This conclusion supports those from economic analyses conducted in EU-member countries.
引用
- Hopkins TJ, Eggington S, Quinn M, et al. Cost-effectiveness of balloon kyphoplasty and vertebroplasty versus conservative medical management in the USA. Osteoporos Int. 2020. PMID: 32656632. doi:10.1007/s00198-020-05513-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。